It is made available under a CC-BY-NC-ND 4.0 International license .

1	In-Hospital and Long-Term Outcomes in Spontaneous Coronary Artery Dissection
2	(SCAD) with Concurrent Cardiac Arrest: A Systematic Review and Meta-Analysis
3	Short title: Outcomes in Spontaneous Coronary Artery Dissection (SCAD) with
4	Concurrent Cardiac Arrest
5	Omar Baqal, MBBS <sup>1*</sup> , Suganya A. Karikalan, MBBS <sup>1,2</sup> , Elfatih A. Hasabo, MBBS <sup>3,4</sup> , Haseeb Tareen, MBBS <sup>1,5</sup> ,
6	Pragyat Futela, MBBS <sup>6,7</sup> , Rakhtan K. Qasba, MBBS <sup>8</sup> , Areez Shafqat, MBBS <sup>9</sup> , Ruman K. Qasba, MBBS <sup>10</sup> ,
7	Sharonne N. Hayes, MD, FACC, FAHA <sup>6</sup> , Marysia S. Tweet, MD, MS <sup>6</sup> , Hicham Z. El Masry, MD, FHRS <sup>1</sup> , Kwan S.
8	Lee, MBBCh, MD, FSCAI <sup>1</sup> , Win-Kuang Shen, MD, FHRS <sup>1</sup> , Dan Sorajja, MD, FHRS <sup>1</sup>
9	<sup>1</sup> Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA
10	<sup>2</sup> CHRISTUS Good Shepherd Medical Center, Longview, Texas, USA
11	<sup>3</sup> CORRIB Research Centre for Advanced Imaging and Core Laboratory, Clinical Science Institute, University of
12	Galway, Galway, Ireland
13	<sup>4</sup> Discipline of Cardiology, Saolta Healthcare Group, Health Service Executive, Galway University Hospital,
14	Galway, Ireland
15	<sup>5</sup> Henry Ford Jackson Hospital, Jackson, Michigan, USA
16	<sup>6</sup> Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
17	<sup>7</sup> MetroHealth Medical Center, Cleveland, Ohio, USA
18	<sup>8</sup> Green Life Medical College and Hospital, Dhaka, Bangladesh
19	<sup>9</sup> College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
20	<sup>10</sup> Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir, India
21	
22	* Corresponding author:
23	Omar Baqal, MBBS
24	Department of Cardiovascular Medicine,
25	Mayo Clinic, Phoenix, Arizona 85054, USA
26	Baqal.omar@mayo.edu

It is made available under a CC-BY-NC-ND 4.0 International license .

27	
28	Disclosures: Dr. Marysia Tweet is supported by a grant from the National Heart, Lung, and Blood Institute,
29	NIH K23H155506. The Mayo Clinic "Virtual" Multicenter SCAD Registry receives support from SCAD Research,
30	Inc.
31	Acknowledgements: Graphical abstract created with BioRender. Blood vessel image in graphical abstract used with
32	permission of Mayo Foundation for Medical Education and Research, all rights reserved.
33	Funding: None
34	
35	Text proper: 3604 words
36	Total word count: 5258 (including Title page, acknowledgements, keywords, table, figure legends, main text and
37	references)
38	Number of references: 42
39	
40	Key words: spontaneous coronary artery dissection, cardiac arrest, ventricular arrhythmia, ventricular fibrillation,
41	ventricular tachycardia, sudden cardiac death, myocardial infarction, defibrillation
42	
72	
43	
44	
45	
46	
47	
48	

It is made available under a CC-BY-NC-ND 4.0 International license .

## 49 Abstract

### 50 Background

- 51 Spontaneous coronary artery dissection (SCAD) is increasingly recognized as an important cause of myocardial
- 52 infarction (MI). However, our understanding of clinical characteristics that predispose patients to worse outcomes,
- 53 such as concurrent sudden cardiac arrest (CA), remains limited.

## 54 Objective

We performed a systematic review and meta-analysis of studies assessing clinical outcomes among SCAD patientswith concurrent CA.

#### 57 Methods

58 This study was performed according to PRISMA guidelines. PubMed, Cochrane, and Scopus were systematically

59 searched using relevant search terms, such as "Spontaneous Coronary Artery Dissection", "Ventricular

60 Tachycardia", "Ventricular Fibrillation", "Sudden Cardiac Death" and "Cardiac Arrest". The search was conducted

from database inception to July 2024. Studies assessing the clinical outcomes of SCAD patients with concurrent CA

62 were included. RevMan 5.4 was used for meta-analysis.

### 63 Results

- 64 After removal of duplicates, 269 studies underwent screening, out of which 10 studies were included (n= 3978
- patients, 357 with CA). In-hospital mortality, post-discharge mortality, recurrent MI and recurrent SCAD occurred
- 66 in 20%, 3%, 12% and 9% of SCAD patients with CA, respectively. When compared to SCAD patients without CA,
- 67 SCAD patients with CA were at significantly higher risk of in-hospital mortality (RR = 6.75, 95% CI [4.50, 10.14],
- 68  $I^2 = 0\%$ ), post-discharge mortality (RR = 5.86, 95% CI [1.72, 19.91],  $I^2 = 0\%$ ), recurrent MI (RR = 3.31, 95% CI [2.03,
- 69 5.39],  $I^2=56\%$ ), recurrent SCAD (RR = 1.91, 95% CI [1.11, 3.27],  $I^2=43\%$ ), acute heart failure (RR = 4.82, 95% CI
- 70 [3.22, 7.20],  $I^2=42\%$ ), and cardiogenic shock (RR = 6.11, 95% CI [4.07, 9.19],  $I^2=64\%$ ). Out of a pooled 24
- 71 implanted cardiac defibrillators (ICDs) and 11 wearable cardiac defibrillators (WCDs), there was only one
- 72 appropriate and one inappropriate ICD discharge recorded over the follow-up period.

### 73 Conclusion

It is made available under a CC-BY-NC-ND 4.0 International license .

- 74 In this cohort, SCAD with concurrent CA was associated with worse in-hospital and long-term outcomes including
- in-hospital and post-discharge mortality, acute heart failure, and recurrent MI and SCAD. There was a low long-
- term rate of administered defibrillator therapies among patients discharged from the hospital with an ICD or WCD.

SCAD with concurrent cardiac arrest (CA)

- 77 Further research is needed to better delineate optimal management approaches toward this high-risk patient
- 78 population, including secondary prevention of sudden cardiac death.
- 79 Graphical abstract



85

80

81

82

83

84

It is made available under a CC-BY-NC-ND 4.0 International license .

# 86 Introduction

87 Spontaneous coronary artery dissection (SCAD) is a form of acute coronary syndrome (ACS) characterized by the 88 non-traumatic, non-iatrogenic intimal tear or separation of the coronary arterial tunica intima and media by an 89 intramural hematoma<sup>1,2</sup>. This is often in the setting of a pre-existing arteriopathy weakening the arterial wall, with 90 additional precipitating emotional or physical stressors that incite the dissection  $^{3-6}$ . Although its true prevalence is 91 unknown, the increasing use of advanced intracoronary imaging techniques and greater awareness has led to SCAD 92 being recognized as an important etiology of ACS. A disease of young-to-middle aged women, SCAD is responsible for 24-35% of cases of ACS in women < 60 years of age<sup>7</sup>. Predisposing conditions to SCAD include fibromuscular 93 dysplasia, inheritable connective tissue diseases, and pregnant/postpartum status<sup>3,4</sup>. The most common presentation 94 95 of SCAD is non-ST segment elevation myocardial infarction (NSTEMI) followed by STEMI, with an estimated 10-20% presenting with cardiac arrest <sup>8</sup>. 96 97 The presence of ventricular arrhythmia (VA) has been reported in 3-13% of patients with SCAD and has been 98 associated with worse in-hospital and long-term outcomes, including mortality and MACE9. Risk stratification for 99 sudden cardiac death (SCD) in SCAD remains poorly explored, and guidelines are unclear on whether or not to 100 pursue ICD implantation in patients with a reversible cause of SCD<sup>9</sup>. Additionally, data remains scarce pertaining to 101 optimal revascularization strategies, timing of ICD implantation, long-term ICD outcomes, and role of wearable

102 cardiac defibrillators (WCDs) at hospital discharge in patients with SCAD and concurrent CA.

103 To consolidate published literature on the topic, we performed a systematic review to explore the impact of

104 concurrent CA in SCAD on in-hospital and long-term clinical outcomes.

# 105 Methods

- 106 This meta-analysis was carried out and reported per the Preferred Reporting Items for Systematic Reviews and
- 107 Meta-analyses (PRISMA)<sup>10</sup>. The study was registered on PROSPERO with registration ID CRD42024511286.

# 108 Literature search

- 109 We performed a search for studies reporting outcomes of people with SCAD complicated by CA, which included
- 110 VT/VF, pulseless electrical activity (PEA) and asystole. Searches were performed on PubMed/MEDLINE,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 111 Cochrane, and Scopus using keywords and standardized index terms, such as "Spontaneous Coronary Artery
- 112 Dissection", "Ventricular Tachycardia", "Ventricular Fibrillation", "Sudden Cardiac Death" and "Cardiac Arrest".
- 113 The search was conducted from date of database establishment to July 2024.
- 114 Inclusion and exclusion criteria for identification of studies
- 115 Articles were considered eligible for inclusion if they were written in English, were peer-reviewed observational
- 116 studies or randomized clinical trials; included adults  $\geq$  18 years of age, reported on outcomes of patients with SCAD
- and concurrent CA, and included information on hospital follow-up and longer. Studies that did not report on the
- distinct outcomes of SCAD with CA, included participants under 18 years of age, or those with no hospital or post-
- discharge follow-up were excluded. We also excluded meta-analyses, systematic reviews, case reports, abstracts,
- editorials, commentaries, and letters to the editor.

## 121 Data screening

- 122 Two reviewers (SK and HT) screened the title and abstracts of all retrieved studies using the pre-defined selection
- 123 criteria. The full texts of studies meeting the criteria were reviewed by OB and RQ. Any disagreements regarding
- 124 article inclusion were resolved after discussing with the senior reviewer (DS).

### 125 Data extraction

- 126 Two authors (HT and OB) extracted data simultaneously into a standard data extraction sheet. The data collected
- 127 included in-hospital overall mortality, post-discharge overall mortality, major adverse cardiovascular events
- 128 (MACE) acute heart failure, cardiogenic shock, LVEF (%), recurrent MI, and recurrent SCAD which predominantly
- 129 included recurrent de novo SCAD. Post-discharge mortality was defined as mortality after hospital discharge over
- 130 follow-up period. Cardiac arrest either on presentation (including out-of-hospital cardiac arrest) or index in-hospital
- 131 cardiac arrest was considered. In-hospital and long-term recurrent MI and SCAD on follow-up were included. Any
- 132 discrepancies were resolved after consulting the senior reviewer (DS).

### 133 Assessment of methodological quality and risk of bias

134 The reviewers then assessed the risk of bias for each study using the Newcastle-Ottawa Scale (NOS) for prospective135 and retrospective cohort studies, and adapted NOS for studies without control arm (Total score is 6). The NOS rates

It is made available under a CC-BY-NC-ND 4.0 International license .

- 136 observational cohort studies based on the selection of participants, comparability between the exposed and
- 137 unexposed groups, and the assessment of the association between exposure and outcome. Studies with a score <5 are
- 138 considered to be of low quality. All included studies scored  $\geq 5$ . (Supplementary material)

# 139 Statistical analysis

- 140 Data were extracted, and the results were presented as risk ratio (RR) and pooled percentage. For single-arm meta-
- 141 analysis; we applied the formula:  $SE = \sqrt{p (1-p)}/n$ , where p stands for prevalence to calculate SE. Heterogeneity was
- 142 assessed using the  $I^2$  test, which calculates percentage variability in endpoints that is due to heterogeneity rather than
- 143 to chance. The larger the  $I^2$ , the more likely that any observed statistical outcomes are due to heterogeneity. An  $I^2$
- 144 <30% for an outcome of interest was set as the standard for low heterogeneity. All statistical tests were 2-sided, and
- 145 a *P*-value <0.05 was considered statistically significant. We used the random-effects model in the presence of
- significant heterogeneity (p <0.1). The statistical analysis was performed using RevMan 5.4. The primary outcome
- 147 of our study was to compare in-hospital overall mortality between SCAD patients with and without CA. Secondary
- 148 outcomes of interest included post-discharge overall mortality, acute heart failure, cardiogenic shock, recurrent MI,
- 149 recurrent SCAD, and  $LVEF \le 40\%$ . Finally, to assess for publication bias, we constructed funnel plots to assess
- 150 asymmetry for each effect estimate and Egger's test as a statistical test of funnel plot asymmetry. (Supplementary
- 151 material)

# 152 **Results**

### 153 Search results and study characteristics

154 A total of 269 non-duplicate study abstracts and titles were screened. Following the pre-defined exclusion and

155 inclusion criteria, 10 studies were selected for inclusion (**Figure 1**)<sup>5,9,11-17</sup>. Detailed study characteristics are outlined

- in **Table 1.** Out of 10 included studies, two were prospective  $^{13,15}$ , and eight were retrospective  $^{5,9,12,14,16-19}$ . The
- 157 studies represented various geographical regions, with four studies from the United States <sup>5,9,12,14,19</sup>, two from
- 158 Canada <sup>13,15</sup>, one from Switzerland <sup>11</sup>, one from Italy <sup>17</sup>, one from Italy and Spain <sup>18</sup>, and one from the Middle East
- 159 (Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, and Bahrain)<sup>16</sup>. A total of 3978 SCAD patients were
- 160 included, out of which 357 (9%) had concurrent CA. In addition to VT/VF, Giacobbe et al.<sup>18</sup> and Phan et al.<sup>14</sup>
- 161 included PEA and asystole in their definition of cardiac arrest. Two studies reported CA on presentation, three

It is made available under a CC-BY-NC-ND 4.0 International license .

- 162 studies reported CA on presentation and during hospitalization, and five studies did not specify CA timing. Six
- 163 studies included SCAD confirmed by coronary imaging, including angiography. Daoulah et al. (51%), Krittanawong
- tal (64%) and Tan et al. (78%) reported the lowest proportions of SCAD patients of female sex. Pooled patient
- sample was predominantly of female sex and <65 years of age.
- 166



167

**168** Figure 1: Flow diagram of literature search and selection of publications.

169

- 170
- 171
- 172
- 173

	Study	Type of Study	Definition of CA	Total no. of SCAD patients	Patients with CA (n, %)	CA on presentation (n, % of total CA)	Follow-up duration (months)	Duration of hospital stay (days)	Angiographic confirmation of SCAD? (Y/N)	Age (years)	Female n (%)	Defibrillator therapies	Defibrillator outcomes	SCAD type (% overall) ¶	Overall revascularization (n, %)
	Giacobbe 2024 <sup>18</sup>	Retrospective	PEA, asystole, VF, pulseless VT	375	20 (5)	6 (30) at presentation 14 (70) in-hospital	21 (10.7–46) (median)	$7.5 \pm 0.49$	Y	52.6 ± 10.2	315 (84)	1 ICD 2 WCDs	-	Type 1: 23% Type 2: 50% Type 3: 6% Type 4: 26%	PCI: 130 (35%) CABG: 1 (0.2%)
	Tan 2023 <sup>12</sup>	Retrospective (NRD)	ICD-10 codes for VT and VF	877	118 (13)	Not specified	1	7.8 ± 8.3	N	52.6 ± 13.8	687 (78)	-	-	-	-
medRxiv	Antonutti 2021	Retrospective	Sustained VT/VF	70	7 (10)	Not specified	39.1 (IQR 13.9 - 86.6) (median)	-	Y	52 (47-58)	60 (86)	-	-	Type 1: 56% Type 2: 43% Type 3: 1%	PCI: 13% CABG: 3%
preprint (wh	ch was not certified by p Cheung 2020 <sup>13</sup> It	<mark>eer review)</mark> is the aut s n <b>ସିତେ:ସୁଦନ୍ଧାର୍ଥାନ</b> ଙ୍କାnd	hor/funder, who has grante eSustained Wit 40 Fht	d medRxiv a licens ernatioh956ense .	e to display the prep 84 (8)	rint in perpetuity. Not specified	57.6 ± 39.6 (mean)	-	Y	49.3 ± 11.3	941 (89)	8 ICDs	1 shock for VT/VF	-	Overall: 174 (16.5%)
	Phan 2020 <sup>14</sup>	Retrospective	Cardiac arrest, including PEA, asystole, VT/VF	208	11 (5)	Not specified	56.4 ± 37.2 (mean)	-	Y	48.53 ± 12.06	186 (94)	2 ICDs 1 WCD	0 shocks	-	PCI: 23 (11%) CABG: 9 (4.6%)
	Krittanawong 2020 <sup>5</sup>	Retrospective	Not specified	375	20 (5)	Not specified	-	-	Ν	52.2 ± 12.8 (overall)	241 (64)	-	-	-	-
	Daoulah 2020 <sup>16</sup>	Retrospective	Sustained VT/VF	83	10 (12)	10 (100)	18.8 (IQR 9.0-40.1) (median)	-	Y	46 (26–81)	42 (51)	1 ICD	1 death confirmed 10 months post- discharge, unknown cause	Type 1: 52% Type 2: 42% Type 3: 4%	Overall: 60% PCI: 53% CABG: 7%
	Chen 2020 <sup>9</sup>	Retrospective	VT/VF	349	20 (6)	17 (85)	69.6 ± 54 (mean)	-	Not specified	47 ± 12	19 (95) for CA group	5 ICDs 4 WCDs	0 shocks	-	PCI: 7 (2%)
	Saw 2017 <sup>15</sup>	Prospective	VT/VF	327	29 (9)	29 (100)	37.2 (IQR 17.9 - 65.9) (median)	3 (IQR 2-5) (median)	Y	52.5 ± 9.6 (overall)	297 (91)	9 "cardioversion or ICD"	-	Type 1: 26% Type 2: 70% Type 3: 5%	Overall: 61 (18.7%) PCI: 16.5% CABG: 2.1%
	Sharma 2017 <sup>19</sup>	Retrospective	Not specified	102	14 (14)	7 (50) OOH 4 (29) in ED 3 (21) during/shortly after PCI	42 (mean)	-	Not specified	44 ± 11	88 (86)	7 ICDs 4 WCDs	1 shock for SVT	Not specified	PCI: 37 (36%) CABG: 3 (3%)

CA: Cardiac arrest, NRD: National Readmissions Database, OOH: Out of hospital, ED: Emergency department, PCI: percutaneous coronary intervention, SVT: Supraventricular tachycardia \* Data cited is for SCAD patients with CA unless specified otherwise

¶ Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. *Catheter Cardiovasc Interv.* 2014;84(7):1115-1122.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 174 Clinical outcomes

- 175 A single-arm meta-analysis was performed to assess the prevalence of study endpoints among SCAD patients with
- 176 concurrent CA. A pooled analysis revealed that in-hospital mortality, post-discharge mortality, recurrent MI and
- 177 recurrent SCAD occurred in 20%, 3%, 12% and 9% of SCAD patients with CA, respectively. (Figure 2). Out of a
- 178 pooled 24 ICDs and 11 WCDs, there was only one appropriate ICD discharge reported for VT/VF, and one
- 179 inappropriate ICD discharge for supraventricular tachycardia (SVT) (Table 1).
- 180
- **181 Figure 2:**

## 182 A. In-hospital mortality



# 183

### **B.** Post-discharge mortality



186 **C.** Recurrent MI

It is made available under a CC-BY-NC-ND 4.0 International license .



187

## 188 **D.** Recurrent SCAD



189

### 190 Outcomes among SCAD patients with CA compared to SCAD patients without CA

191

#### **192** In-hospital overall mortality:

- 193 Seven studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
- higher in-hospital overall mortality compared to SCAD patients without CA (27/295 vs 47/2900, RR = 6.75, 95% CI
- **195** [4.50, 10.14], P < 0.00001,  $I^2 = 0\%$ ). (Figure 3A)

196

### **197** Post-discharge overall mortality:

198 Four studies were included in the meta-analysis. Follow-up ranged from 18.8 to 39.1 months for studies reporting

median follow-up and 42.0 to 69.6 months for studies reporting mean follow-up. NRD-based study by Tan et al.

assessed 1-month post-discharge outcomes. The pooled results showed that SCAD patients with CA had higher

201 post-discharge overall mortality compared to SCAD patients without CA (3/127 vs 7/1488, RR = 5.86, 95% CI

202 [1.72, 19.91], P = 0.005,  $I^2 = 0\%$ ). (Figure 3B)

203

#### 204 Major adverse cardiovascular events (MACE)

It is made available under a CC-BY-NC-ND 4.0 International license .

205	Four studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
206	higher risk of MACE compared to SCAD patients without CA (29/121 vs 180/1463, RR = 1.91, 95% CI [1.11, 3.27],
207	$P=0.02$ , $I^2=77\%$ ). High heterogeneity was noted, potentially attributable to varying definitions of MACE across
208	studies. (Figure 3C)
209	
210	Acute heart failure:
211	Three studies were included in the meta-analysis and the pooled results showed that SCAD patients with CA had
212	higher risk of acute heart failure compared to SCAD patients without CA (34/212 vs 49/1804, RR = 4.82, 95% CI
213	[3.22, 7.20], P < 0.00001) (I <sup>2</sup> = 42%). (Figure 3D)
214	
215	Cardiogenic shock:
216	Two studies were included, and the pooled results showed that SCAD patients with CA had higher risk of
217	cardiogenic shock compared to SCAD patients without CA (37/128 vs 39/832, RR = 6.11, 95% CI [4.07, 9.19],
218	$P < 0.00001$ ) ( $I^2 = 64\%$ ). (Figure 3E)
219	
220	Recurrent MI
221	Three studies were included, and the pooled results showed that SCAD patients with CA had higher risk of recurrent
222	MI compared to SCAD patients without CA (16/114 vs 134/1400, RR =3.31, 95% CI [2.03, 5.39], P < 0.00001),
223	I <sup>2</sup> =56%) (Figure 3F)
224	
225	Recurrent SCAD
226	Recurrent SCAD primarily included recurrent de novo SCAD, and not SCAD extension. Five studies were included,
227	and the pooled results showed no significant difference in SCAD recurrence between SCAD patients with CA
228	compared to SCAD patients without CA (14/135 vs 84/1551, RR = 2.48, 95% CI [0.59, 10.47], P = 0.22) ( $I^2 = 65\%$ ).
229	(Figure 3G)
230	

231 LVEF  $\leq 40\%$ 

It is made available under a CC-BY-NC-ND 4.0 International license .

- 232 Three studies were included, and the pooled results showed that SCAD patients with CA had higher risk of LVEF  $\leq$
- 233 40% compared to SCAD patients without CA (20/105 vs 52/1242, RR = 5.26, 95% CI [2.78, 9.94], P < 0.00001) ( $I^2$ =
- **234** 0%). (Figure 3H)
- 235
- 236 **Figure 3**:

# **A.** In-hospital overall mortality

	SCAD +	F CA	SCAD witho	out CA	Risk Ratio			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Saw et al. 2017	0	29	0	298		Not estimable	2017	
Sharma et al. 2017	0	14	0	88		Not estimable	2017	
Krittanawong et al. 2020	15	21	28	311	44.1%	7.93 [5.08, 12.38]	2020	-
Cheung et al. 2020	1	84	1	972	2.0%	11.57 [0.73, 183.35]	2020	
Daoulah et al. 2020	1	10	0	73	1.6%	20.18 [0.88, 465.03]	2020	
Tan et al. 2023	12	118	15	759	50.2%	5.15 [2.47, 10.72]	2023	<b>-∎</b>
Giacobbe et al. 2024	0	20	1	355	2.1%	5.65 [0.24, 134.56]	2024	
Total (95% CI)		296		2856	100.0%	6.75 [4.50, 10.14]		◆
Total events	29		45					
Heterogeneity: Chi <sup>2</sup> = 1.66, df = 4 (P = 0.80); I <sup>2</sup> = 0%								
Test for overall effect: Z = 9.21 (P < 0.00001)							Favors [SCAD without CA] Favors [SCAD + CA]	

## **B.** Post-discharge overall mortality

SCAD + CA		+ CA	SCAD witho	ut CA		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl		
Sharma et al. 2017	0	14	0	88		Not estimable	2017			
Cheung et al. 2020	2	84	6	972	76.9%	3.86 [0.79, 18.81]	2020			
Daoulah et al. 2020	1	9	0	73	9.6%	22.20 [0.97, 508.69]	2020	•		
Giacobbe et al. 2024	0	20	1	355	13.5%	5.65 [0.24, 134.56]	2024			
Total (95% CI)		127		1488	100.0%	5.86 [1.72, 19.91]		-		
Total events	3		7							
Heterogeneity: $Chi^2 = 0.96$ , $df = 2 (P = 0.62)$ ; $l^2 = 0\%$							4000			
Test for overall effect: Z = 2.83 (P = 0.005)						Favors [SCAD without CA] Favors [SCAD + CA]	1000			

## 240

241

238

# **C.** Major adverse cardiovascular event (MACE)

SCAD + CA SCAD without CA		out CA	Risk Ratio			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight M-H, Random, 95% Cl Yea:		Year	M-H, Random, 95% Cl		
Cheung et al. 2020	17	84	116	972	31.3%	1.70 [1.07, 2.68]	2020			
Daoulah et al. 2020	5	10	3	73	20.4%	12.17 [3.42, 43.31]	2020			
Antonutti et al. 2021	4	7	8	63	25.3%	4.50 [1.81, 11.20]	2021	│ <b></b> ∎		
Giacobbe et al. 2024	3	20	53	355	23.0%	1.00 [0.34, 2.94]	2024			
Total (95% CI)		121		1463	100.0%	2.88 [1.16, 7.13]		◆		
Total events	29		180							
Heterogeneity: Tau <sup>2</sup> = 0.63; Chi <sup>2</sup> = 12.88, df = 3 (P = 0.005); I <sup>2</sup> = 779				= 77%				1000		
Test for overall effect: Z = 2.28 (P =		= 0.02	)					Favors [SCAD without CA] Favors [SCAD + CA]	1000	

<sup>242</sup> 

243



#### It is made available under a CC-BY-NC-ND 4.0 International license .



### 

## 246 E. Cardiogenic Shock



#### **F.** Recurrent MI

	SCAD + CA		SCAD without CA			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl		
Cheung et al. 2020	14	84	32	972	50.8%	5.06 [2.81, 9.11]	2020	— <b>—</b> —		
Daoulah et al. 2020	1	10	5	73	12.0%	1.46 [0.19, 11.26]	2020			
Giacobbe et al. 2024	3	20	35	355	37.2%	1.52 [0.51, 4.52]	2024			
Total (95% CI)		114		1400	100.0%	3.31 [2.03, 5.39]		•		
Total events	18		72							
Heterogeneity: Chi <sup>2</sup> = 4	4.58, df = 2	(P = 0.	10); <b>P</b> = 56%				L L		400	
Test for overall effect: 2	Z = 4.81 (P	< 0.00	001)				υ.	Favors [SCAD without CA] Favors [SCAD + CA]	100	

### **G.** Recurrent SCAD



**H.** LVEF  $\leq 40\%$ 

It is made available under a CC-BY-NC-ND 4.0 International license .

### 257

	SCAD + VA SCAD without VA			It VA	14/-:-b4	Risk Ratio	¥	Risk Ratio			
	Cheung et al. 2020	12	10tal 84	25	972	91.1%	5.55 [2.90, 10.65]	2020			
	Total (95% CI)	U	94	I	1045	8.9%	5.26 [2.78, 9.94]	2020	•		
	Total events Heterogeneity: Chi <sup>2</sup> = I	12 D.31,df=	1 (P = 0	26 ).58); I² = 0%							
258	Test for overall effect: 2	Z = 5.11 (I	⊃ < 0.00	0001)					U.001 U.1 1 10 Favours [SCAD without VA] Favours [SCAD + VA]	1000	
259											
260											
261											
262											

## 263 Discussion

We present, to the best of our knowledge, the largest analysis on the clinical outcomes in SCAD with concurrent cardiac arrest. Patients with SCAD and CA were at a higher risk of in-hospital and post-discharge mortality, acute heart failure, cardiogenic shock, recurrent MI and recurrent SCAD. Importantly, our results are mostly applicable to SCAD patients with CA who survive at least up to hospital arrival to undergo medical evaluation and additional testing. Those who do not survive to hospital presentation may have unique clinical characteristics and risk factors that are likely largely understudied.

270 Although SCAD is generally associated with good long-term outcomes with low overall mortality and incidence of 271 MACE<sup>4</sup>, our pooled double-arm meta-analysis highlights that patients who develop concurrent CA be considered 272 high-risk for both acute and long-term complications. Nevertheless, cause-specific mortality in these patients is not 273 well explored. Patients with SCAD and CA are more likely to present with STEMI, which is commonly associated 274 with larger infarct size and increased risk of LV dysfunction and adverse cardiovascular outcomes <sup>9</sup>. Krittanawong 275 et al. reported that atrial fibrillation, steroid use, ventricular arrhythmias, and cardiac arrest were independent 276 predictors of in-hospital mortality in SCAD patients<sup>5</sup>. Conservative management at index presentation is typically 277 pursued, although Waterbury et al. highlighted that 17.5% of conservatively managed SCAD patients had early

It is made available under a CC-BY-NC-ND 4.0 International license .

SCAD progression based on angiographic evaluation; specifically, patients with intramural hematoma at baseline
 were at higher risk of progression and early deterioration <sup>20,21</sup>.

Studies on the community-based Canadian SCAD cohort <sup>4</sup>, the Nationwide Readmissions Database <sup>12</sup>, the Mayo
Clinic SCAD Virtual Multi-Center registry <sup>22</sup>, and a multinational study covering four Gulf countries (KSA, UAE,
Kuwait, and Bahrain) <sup>16</sup> have recorded rates of CA between ~3-13% at index hospitalization and ~4% of patients
during post-discharge follow-up, corresponding with our pooled estimates. The reported prevalence of CA in SCAD
patients is more variable, which could be explained by a multitude of reasons, including baseline patient features and
SCAD severity, and time frame over which CA was assessed (e.g., immediate post-event, in-hospital, and long-term
follow-up).

287 Management recommendations for SCAD are based on observational studies, and there are no published 288 randomized control trials yet. Consensus statements by the European Society of Cardiology (ESC) and American 289 Heart Association (AHA) on SCAD recommend medical management when possible for SCAD patients who are hemodynamically stable and do not show signs of ongoing myocardial ischemia<sup>2,23</sup>. Long-term management of 290 291 SCAD involves maintenance on aspirin and beta-blockers, the latter associated with reduced incidence of SCAD 292 recurrence in one observational study <sup>15</sup>. This guidance is based on findings that the dissection will most likely heal 293 spontaneously, and recurrence typically does not involve the initial culprit coronary artery, nor does PCI prevent 294 future SCAD recurrence <sup>21,24</sup>. In our meta-analysis, only three studies had data on beta-blocker usage, although 295 specific data on SCAD patients with concurrent CA was lacking, and use of antiarrhythmic medications was 296 unavailable<sup>11,15,17</sup>. In a prospective, multicenter study by Saw et al. of 750 SCAD patients out of whom 8.3% had 297 VT/VF, aspirin and beta-blocker usage was high with low long-term mortality<sup>4</sup>. Tweet et al. reported an 298 uncomplicated hospital course among 31 SCAD patients managed conservatively, with two deaths occurring on 299 long-term follow-up. In contrast, failure rate of PCI was 53% and it did not significantly reduce rates of revascularization and recurrence of SCAD<sup>24</sup>. One population very much underrepresented in the included studies is 300 301 obstetric patients; pregnancy and the peri-partum period have been posited as major risk factors for SCAD in 302 multiple studies with a more severe presentation <sup>25</sup>. Among 13 deaths attributable to pregnancy-associated SCAD (P-SCAD) in the MBRRACE-UK audit, 12 suffered from an out-of-hospital CA<sup>26</sup>. Phan et al. found that SCAD 303 patients with CA were more likely to have P-SCAD<sup>14</sup>. However, Krittanawong et al. in their analysis based on NRD 304

It is made available under a CC-BY-NC-ND 4.0 International license .

data noted a similar incidence of CA between P-SCAD and non-P-SCAD <sup>27</sup>. Therefore, further research is needed to
 clarify possible risk-enhancing factors for CA and CA-related outcomes in this patient group.

307 Those who receive PCI show no statistical difference in long-term outcomes compared to those who received no

308 PCI, and the former may expose patients to greater risks of iatrogenic complications such as propagation of

intramural hematoma and dissection and abrupt vessel occlusion <sup>4,24,28,29</sup>. This can lead to an increased myocardial

310 ischemic burden and subsequently increased risk of ventricular arrhythmogenicity. Nearly half of the VT/VF arrests

311 reported in their cohort by Phan et al. occurred during PCI<sup>14</sup>. A meta-analysis by Bocchino *et al.* also showed that

the mean success rate of PCI was less than 50% and that revascularization therapies did not decrease rates of all-

313 cause mortality, cardiovascular mortality, myocardial infarction, heart failure, and SCAD recurrence <sup>30</sup>. In light of

314 uncertain benefits and increased risk of bleeding complications associated with antiplatelet therapy in SCAD

315 patients who do not undergo PCI, experts recommend individualized decision-making considering the risk-benefit

316 ratio<sup>2</sup>. Indications for the use of more advanced imaging modalities like intravascular ultrasound (IVUS) and optical

317 coherence tomography (OCT) are also not well defined but may optimize the use of PCI in high-risk patients,

**318** though their uptake in studies has been low  $^{30,31}$ .

319 Notably, based on our pooled sample which included placement of 24 ICDs and 11 WCDs, there was only one appropriate ICD discharge reported for VT/VF by Cheung et al. over a mean follow-up of  $4.8 \pm 3.3$  years, and one 320 inappropriate discharge for SVT<sup>13</sup>,<sup>19</sup>. In a community-based study of 27 patients with VA due to SCAD, Chen *et al.* 321 322 demonstrated that no patient developed recurrent VA due to SCAD and none required defibrillation therapies over a 323 5.8-year mean follow-up<sup>9</sup>. Over a mean follow up period of 3.5 years following ICD placement among seven 324 SCAD patients with SCD as part of the MGH-SCAD registry, there was one inappropriate ICD discharge for 325 supraventricular tachycardia<sup>19</sup>. The unclear risk-benefit ratio of ICD placement for secondary SCD prevention in 326 SCAD was highlighted by Garg et al in their meta-analysis, noting 1.2% (95% CI: 0%–15.8%, I2 = 0%) and 1% 327 (95% CI: 0%–15.3%, I2 = 0%) patients received appropriate and inappropriate ICD therapies, respectively, during 328 the follow-up period <sup>32</sup>. Given these findings and considering that most SCAD lesions heal spontaneously on follow-329 up, current guidelines do not support early ICD implantation for patients after an episode of cardiac arrest with a 330 reversible cause <sup>33,34</sup>. Our results support the idea of SCAD-mediated CA being a transient substrate with a low

331 recurrent event rate, as long as the LVEF recovers. Factors such as incomplete coronary revascularization,

It is made available under a CC-BY-NC-ND 4.0 International license .

persistently reduced LVEF, and recurrent VA can also be used to risk-stratify sudden cardiac death and guide
 decision-making regarding ICD placement <sup>35</sup>. It would be of value for future studies to stratify patient outcomes data
 based on timing of CA – such as out-of-hospital, in-hospital and procedural. Data remains scarce on use of multi modality imaging for determining ICF placement, optimal timing of ICD placement, long-term appropriateness of
 ICD therapies in this patient population and role of WCDs as a bridge to ICD implantation, and further research is
 needed.

We also found that the incidence of recurrent de novo SCAD was higher in SCAD patients with CA. Management
of modifiable factors such as smoking cessation, avoidance of pregnancy, and adherence to long-term medical
therapy with beta-blockers may decrease the risk of recurrent SCAD. The development of VA in SCAD patients can
be related to multiple factors, with only one of them being recurrent SCAD. For instance, myocardial fibrosis after
SCAD-induced MI may also increase the long-term risk of VAs. Hence, future studies evaluating the association
between myocardial fibrosis as assessed by imaging techniques such as cardiac MRI (CMR) and recurrent VAs may

344 reveal new strategies for identifying candidates that may benefit from ICD placement.

345 Indeed, it is well recognized that solely relying on LVEF is inadequate in stratifying SCAD patients' future risk of 346 SCD; the cut-off of LVEF < 35% that guides ICD placement may correctly predict only  $\sim 20\%$  of SCD events in 347 other cardiomyopathies <sup>36</sup>. CMR—particularly late gadolinium enhancement (LGE) to detect myocardial fibrosis— 348 provides additional prognostic information about SCD risk over solely LVEF <sup>37-39</sup>. Replacement of viable 349 myocardial tissue by fibrosis in SCAD is likely to significantly enhance risk of post-SCAD arrhythmias. Hence, 350 characterizing such an arrhythmogenic substrate by CMR-LGE may enhance SCD risk stratification and further 351 guide appropriateness of ICD implantation. In this context, one study of 14 patients with acute or recurrent SCAD demonstrated LGE in the distribution of the culprit coronary artery in all cases <sup>40</sup>. This finding needs to be replicated 352 353 in larger cohorts. Patient populations who would benefit most from CMR-based characterization of scar tissue 354 require further defining. For instance, Androulakis et al. demonstrated that SCAD involving the RCA was predictive of myocardial fibrosis detected by LGE (OR = 5.2; p = 0.034)<sup>41</sup>. Additionally, most patients with SCAD may not 355 356 present with large infarct sizes and subsequent myocardial fibrosis; however, those with pregnancy-related SCAD, 357 multi-vessel SCAD, STEMI, CA, extracoronary arteriopathies (e.g., fibromuscular dysplasia, focal stenoses, and

medRxiv preprint doi: https://doi.org/10.1101/2024.09.25.24314406; this version posted September 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

arterial tortuosity) are more likely to present with larger infarct sizes and may therefore benefit from further
 anatomical and functional characterization by CMR and LGE <sup>41,42</sup>.

## 360 Limitations

361 All included studies were observational in nature, with results impacted by the completeness of collected and 362 analyzed data. Tan et al. was a database study utilizing the National Readmissions Database and used ICD coding 363 for coronary artery dissection due to lack of specific ICD-10 codes for SCAD, possibly contributing to heterogeneity 364 of studied patients due to potential inclusion of iatrogenic coronary artery dissection and atherosclerotic coronary 365 artery dissection. Similarly, Krittanawong et al. was an ICD-9 or -10 codes-based study without angiogram 366 confirmation which may contribute to heterogeneity. These studies had a higher proportion of men, suggesting that 367 some of the patients may have had dissection in the setting of atherosclerosis. As our study was a systematic review 368 and meta-analyses of published observational studies, some results may be hindered by publication biases. 369 Heterogeneity was noted among several variables, which can be attributed to differences in study populations, 370 definitions of endpoints, and other clinical and/or procedural variables. Differences in population characteristics, 371 interventions, and outcomes measured can create discrepancies that make it challenging to draw generalized 372 conclusions. Similarly, these cohorts only included patients who survived long enough to be diagnosed with SCAD 373 and did not include autopsy data. SCAD is a particularly important clinical entity among obstetric patients, although 374 our review noted data on this patient group to be lacking and so was literature on sex-based differences in outcomes. 375 Further research is needed to explore outcomes in women and obstetric patients with SCAD and CA. Due to 376 limitations in the reported literature, our study did not focus on sex-based differences or pregnancy associated 377 SCAD. Although our study is, to the best of our knowledge, the largest to study clinical outcomes in SCAD patients 378 with CA, it is important to acknowledge that these findings are hypothesis-generating and may not be powered 379 sufficiently to guide clinical care in a diverse patient population with varying characteristics and risk factors.

380

### 381 Conclusions

382 Our systematic review and meta-analyses highlight that concurrent CA in SCAD is associated with worse in-hospital383 and post-discharge mortality, and higher risk of acute heart failure, cardiogenic shock, recurrent MI and recurrent

It is made available under a CC-BY-NC-ND 4.0 International license .

384	SCAD.	Pooled follow-up ICD and WCD data noted a low recurrent CA event rate. Our findings support SCAD-								
385	mediate	d CA to be a transient substrate, supporting a conservative approach to secondary CA prevention in SCAD								
386	consistent with the current recommendation for atherosclerotic CAD/MI-mediated CA. Further research is needed									
387	on various aspects of management relevant to this high-risk patient population, including patient selection for ICD									
388	placeme	nt and the role of WCDs in managing early recurrent SCD.								
389										
390										
391										
392	Referen	ices								
393										
394	1.	Tweet MS, Hayes SN, Pitta SR et al. Clinical features, management, and prognosis of spontaneous								
395		coronary artery dissection. Circulation 2012;126:579-88.								
396	2.	Hayes SN, Kim ESH, Saw J et al. Spontaneous Coronary Artery Dissection: Current State of the Science:								
397		A Scientific Statement From the American Heart Association. Circulation 2018;137:e523-e557.								
398	3.	Saw J, Starovoytov A, Humphries K et al. Canadian spontaneous coronary artery dissection cohort study:								
399		in-hospital and 30-day outcomes. Eur Heart J 2019;40:1188-1197.								
400	4.	Saw J, Starovoytov A, Aymong E et al. Canadian Spontaneous Coronary Artery Dissection Cohort Study.								
401		Journal of the American College of Cardiology 2022;80:1585-1597.								
402	5.	Krittanawong C, Kumar A, Wang Z et al. Clinical features and prognosis of patients with spontaneous								
403		coronary artery dissection. Int J Cardiol 2020;312:33-36.								
404	6.	Stanojevic D, Apostolovic S, Kostic T et al. A review of the risk and precipitating factors for spontaneous								
405		coronary artery dissection. Front Cardiovasc Med 2023;10:1273301.								
406	7.	Saw J, Aymong E, Mancini GB, Sedlak T, Starovoytov A, Ricci D. Nonatherosclerotic coronary artery								
407		disease in young women. Can J Cardiol 2014;30:814-9.								
408	8.	García-Guimarães M, Sanz-Ruiz R, Sabaté M et al. Spontaneous coronary artery dissection and ST-								
409		segment elevation myocardial infarction: Does clinical presentation matter? Int J Cardiol 2023;373:1-6.								

It is made available under a CC-BY-NC-ND 4.0 International license .

- 410 9. Chen S, Ambrosy AP, Mahrer KN, Lundstrom RJ, Naderi S. Spontaneous Coronary Artery Dissection and
- Incident Ventricular Arrhythmias: Frequency, Clinical Characteristics, and Outcomes. JACC Cardiovasc
   Interv 2020;13:539-541.
- 413 10. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for
- 414 reporting systematic reviews. Bmj 2021;372:n71.
- 415 11. Würdinger M, Schweiger V, Gilhofer T et al. Twenty-five-year trends in incidence, angiographic
- 416 appearance, and management of spontaneous coronary artery dissection. Int J Cardiol 2024;395:131429.
- 417 12. Tan MC, Yeo YH, Ang QX et al. Hospital Outcomes of Spontaneous Coronary Artery Dissection With
- 418 Concurrent Ventricular Arrhythmias. Journal of the Society for Cardiovascular Angiography &
- 419 Interventions 2024;3:101231.
- 420 13. Cheung CC, Starovoytov A, Parsa A et al. In-hospital and long-term outcomes among patients with
  421 spontaneous coronary artery dissection presenting with ventricular tachycardia/fibrillation. Heart Rhythm
  422 2020;17:1864-1869.
- 423 14. Phan D, Clare R, Duan L, Kim C, Moore N, Lee M-S. Characteristics and outcomes of patients with
  424 spontaneous coronary artery dissection who suffered sudden cardiac arrest. Journal of Interventional

425 Cardiac Electrophysiology 2021;60:77-83.

- 426 15. Saw J, Humphries K, Aymong E et al. Spontaneous Coronary Artery Dissection: Clinical Outcomes and
  427 Risk of Recurrence. J Am Coll Cardiol 2017;70:1148-1158.
- 428 16. Daoulah A, Al-Faifi SM, Alsheikh-Ali AA, Hersi AS, Lotfi A. Ventricular Arrhythmias in Patients with
- 429 Spontaneous Coronary Artery Dissection: Findings from the Gulf Spontaneous Coronary Artery Dissection
- 430 (Gulf SCAD) Registry. Crit Pathw Cardiol 2020;19:146-152.
- 431 17. Antonutti M, Baldan F, Lanera C et al. Spontaneous coronary artery dissection: Role of prognostic markers
  432 and relationship with genetic analysis. International Journal of Cardiology 2021;326:19-29.
- 433 18. Giacobbe F, Bruno F, Brero M et al. Spontaneous coronary artery dissection (SCAD) with cardiac arrest at
  434 presentation: A subanalysis from the DISCO registry. Int J Cardiol 2024;412:132331.
- 435 19. Sharma S, Rozen G, Duran J, Mela T, Wood MJ. Sudden Cardiac Death in Patients With Spontaneous
- 436 Coronary Artery Dissection. Journal of the American College of Cardiology 2017;70:114-115.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 437 20. Waterbury TM, Tweet MS, Hayes SN et al. Early Natural History of Spontaneous Coronary Artery
- 438 Dissection. Circ Cardiovasc Interv 2018;11:e006772.
- 439 21. Hassan S, Prakash R, Starovoytov A, Saw J. Natural History of Spontaneous Coronary Artery Dissection
- 440 With Spontaneous Angiographic Healing. JACC Cardiovasc Interv 2019;12:518-527.
- 441 22. Kok SN, Hayes SN, Cutrer FM et al. Prevalence and Clinical Factors of Migraine in Patients With
- 442 Spontaneous Coronary Artery Dissection. J Am Heart Assoc 2018;7:e010140.
- 443 23. Adlam D, Alfonso F, Maas A, Vrints C, Writing C. European Society of Cardiology, acute cardiovascular
- 444 care association, SCAD study group: a position paper on spontaneous coronary artery dissection. European
  445 Heart Journal 2018;39:3353-3368.
- 446 24. Tweet MS, Eleid MF, Best PJ et al. Spontaneous coronary artery dissection: revascularization versus
  447 conservative therapy. Circ Cardiovasc Interv 2014;7:777-86.
- 448 25. Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous Coronary Artery Dissection
  449 Associated With Pregnancy. Journal of the American College of Cardiology 2017;70:426-435.
- 450 26. Knight M, Tuffnell D. A View From the UK: The UK and Ireland Confidential Enquiry into Maternal
  451 Deaths and Morbidity. Clin Obstet Gynecol 2018;61:347-358.
- 452 27. Krittanawong C, Patel N, Bandyopadhyay D et al. Spontaneous coronary artery dissection outcomes among

453 pregnant vs. non-pregnant women. Eur Heart J Acute Cardiovasc Care 2024;13:423-428.

- 454 28. Hayes SN, Tweet MS, Adlam D et al. Spontaneous Coronary Artery Dissection: JACC State-of-the-Art
  455 Review. Journal of the American College of Cardiology 2020;76:961-984.
- 456 29. Prakash R, Starovoytov A, Heydari M, Mancini GB, Saw J. Catheter-Induced Iatrogenic Coronary
- 457 Artery Dissection in Patients With Spontaneous Coronary Artery Dissection. JACC Cardiovasc Interv
  458 2016;9:1851-3.
- 30. Bocchino PP, Angelini F, Franchin L et al. Invasive versus conservative management in spontaneous
  coronary artery dissection: A meta-analysis and meta-regression study. Hellenic J Cardiol 2021;62:297303.
- 462 31. Paulo M, Sandoval J, Lennie V et al. Combined use of OCT and IVUS in spontaneous coronary artery
  463 dissection. JACC Cardiovasc Imaging 2013;6:830-2.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 464 32. Garg J, Shah K, Shah S, Turagam MK, Natale A, Lakkireddy D. Implantable cardioverter-defibrillator in
- patients with spontaneous coronary artery dissection presenting with sudden cardiac arrest. J Cardiovasc
  Electrophysiol 2021;32:2595-2600.
- 467 33. Russo Andrea M, Poole Jeanne E. Secondary Prevention. JACC: Clinical Electrophysiology 2017;3:29-32.
- 468 34. Al-Khatib SM, Stevenson WG, Ackerman MJ et al. 2017 AHA/ACC/HRS Guideline for Management of
- 469 Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the
- 470 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
- 471 and the Heart Rhythm Society. J Am Coll Cardiol 2018;72:e91-e220.
- 472 35. Ragupathi L, Pavri BB. Tools for risk stratification of sudden cardiac death: a review of the literature in
  473 different patient populations. Indian Heart J 2014;66 Suppl 1:S71-81.
- Wellens HJ, Schwartz PJ, Lindemans FW et al. Risk stratification for sudden cardiac death: current status
  and challenges for the future. Eur Heart J 2014;35:1642-51.
- 476 37. Halliday BP, Gulati A, Ali A et al. Association Between Midwall Late Gadolinium Enhancement and
  477 Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular
  478 Systolic Dysfunction. Circulation 2017;135:2106-2115.
- 479 38. Di Marco A, Anguera I, Schmitt M et al. Late Gadolinium Enhancement and the Risk for Ventricular
- 480 Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC
  481 Heart Fail 2017;5:28-38.
- 482 39. Li S, Wang Y, Yang W et al. Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left
  483 Ventricular Ejection Fraction of 35% or Higher. Radiology 2023;306:e213059.
- 484 40. Chandrasekhar J, Thakkar J, Starovoytov A, Mayo J, Saw J. Characteristics of spontaneous coronary artery
  485 dissection on cardiac magnetic resonance imaging. Cardiovasc Diagn Ther 2020;10:636-638.
- 486 41. Androulakis E, Azzu A, Papagkikas P et al. Spontaneous Coronary Artery Dissection: Insights From
- 487 Cardiac Magnetic Resonance and Extracoronary Arterial Screening. Circulation 2022;145:555-557.
- 488 42. Al-Hussaini A, Abdelaty A, Gulsin GS et al. Chronic infarct size after spontaneous coronary artery
- dissection: implications for pathophysiology and clinical management. Eur Heart J 2020;41:2197-2205.
- 490

# 491 Supplementary material

It is made available under a CC-BY-NC-ND 4.0 International license .

# 492

# 493 Supplementary table 1: Quality assessment of included studies using adapted Newcastle-

494 Ottawa Scale (NOS)

Study	Selection	Comparability	Outcome	Total score
Giacobbe et al. 2024	3	1	3	6
Antonutti et al. 2021	3	-	3	6
Tan et al. 2023	3	1	3	7
Cheung et al. 2020	4	0	3	7
Krittanawong et al. 2020	4	0	1	5
Phan et al. 2020	4	1	2	7
Saw et al. 2017	3	-	2	5
Chen et al. 2020	3	-	2	5
Daoulah et al. 2020	3	1	2	6
Sharma et al. 2017	3	1	2	6

495

496

498 (A) In hospital overall mortality, (B) Post-discharge overall mortality, (C) Acute heart failure, (D)

499 Cardiogenic shock, (E) MACE (F) Recurrent MI, (G) Recurrent SCAD, (H)  $LVEF \le 40\%$ 

500

501

502

(A)

503

<sup>497</sup> Supplementary Figure 2: Publication bias for the outcomes of SCAD with CA vs SCAD without CA:



It is made available under a CC-BY-NC-ND 4.0 International license .

0+SE(log[RR]) Ο 0.5-1 0 1.5 0 0 RR 1000 2 0.001 10 0.1 **(B)** SE(log[RR]) 0-0.5 0 1 1.5 0 RR 1000 2 0.001 10 0.1 1

506

504

505

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license . SE(log[RR]) 0-0.5-1 0 1.5 RR 1000 2 0.001 10 0.1 510 511 **(E)** SE(log[RR]) 0-0.2 0 0.4 0 0 0.6 0 0.8

0.1

10

1

medRxiv preprint doi: https://doi.org/10.1101/2024.09.25.24314406; this version posted September 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

1 <del>|</del> 0.001

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .



523

SCAD with concurrent cardiac arrest (CA)

(N= 3978; 357 [9%] with CA)

